KH-001 ODT

Phase 2Small molecule

KKadence Bio

KH-001 ODT is one of 28 small molecule programs targeting Premature Ejaculation. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Premature EjaculationActive, not recruiting

Premature EjaculationPhase 2

Active, not recruiting

Competition

Competitive Landscape

38 competitors in Premature Ejaculation

#DrugCompanyPhaseTrials

Xylocaine

MMEDRx USA, Inc.

Approved

1 2

Viagra

VViatris Specialty LLC

Approved

1 3

Cialis

Eli Lilly

Phase 3

2 4

Ultram

Haisco Pharmaceutical Group Co., Ltd.

Phase 3

2 5

Restasis

TTaiwan Bio Therapeutics Inc.

Phase 3

2 6

Paxil

SSebela Pharmaceuticals Development LLC

Phase 3

2 7

Botox

AbbVie

Phase 3

1 8

Rapaflo

AbbVie

Phase 2

1 9

Anafranil

SSpecgx

Phase 3

2 10

Standard Treatment

Boehringer Ingelheim

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Recruiting

Premature Ejaculation

NCT07434271

Clinical

Trials by Indication[1]

Premature Ejaculation1 trial

Study to Evaluate the Potential Effects of KH-001 on Intravaginal Ejaculatory Latency Time (IELT), Patient-Reported Outcomes, and Safety in Men With Lifelong Premature Ejaculation (LPE)

Recruiting·KKadence Bio·Phase 2·NCT07434271·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for KH-001 ODT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — KH-001 ODT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for KH-001 ODT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kadence Bio company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: KKadence Bio

KH-001 ODT

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Premature Ejaculation1 trial

References

Drug Info

Quick Facts

Related News